Whitehawk Highlights SEZ6 as Promising ADC Target in SCLC at ASCO 2026
MORRISTOWN, N.J., May 30, 2026 Whitehawk Therapeutics announced new real-world data at the 2026 American Society of Clinical Oncology...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
MORRISTOWN, N.J., May 30, 2026 Whitehawk Therapeutics announced new real-world data at the 2026 American Society of Clinical Oncology...
